Theravance Inc: (NASD: THRX)
$40.96
-0.91 (-2.17%)
Volume 1,356,255
May 15 03:47 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 40.69 - 42.03 |
| 52wk Low - High | 17.06 - 42.41 |
| Previous Close | 41.87 |
| Avg. Volume | 2,533,470 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 4.16 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.39 |
| PE (Forward) | 0.00 |
| Current Year Est. | -2.32 |
| Quarterly Earnings ESP |
1.75% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
79 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.32 |
| Current Quarter Estimate | -0.57 |
| Most Accurate Estimate | -0.56 |
| Earnings ESP |
1.75% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -1.51 |
| Expected Earnings Growth | NA |
Company Description
Theravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.57 | -1.26 | -2.32 | -0.62 |
| Number of Estimates | 4 | 3 | 5 | 4 |
| Low Estimate | -0.84 | -2.61 | -3.71 | -1.04 |
| High Estimate | -0.34 | -0.34 | -1.33 | NA |
| Year Ago EPS | -0.42 | -0.37 | -0.20 | -2.32 |
| EPS Growth | -36.31% | -239.64% | -1,058.00% | 73.34% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| THERAVANCE INC | THRX | 41.87 | |
|
| AETERNA ZENTARS | AEZS | 1.91 | |
|
| ALKERMES INC | ALKS | 31.35 | |
|
| ANIKA THERAPEUT | ANIK | 14.10 | |
|
| GENTIUM SPA-ADR | GENT | 8.67 | |
|
| NOVELOS THERAPT | NVLT | 0.46 | |
|
| TRANZYME INC | TZYM | 0.58 | |
|
| AASTROM BIOSCI | ASTM | 0.60 | |
|
| ACHILLION PHARM | ACHN | 7.30 | |
|
| AFFYMAX INC | AFFY | 1.42 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Elan in Royalty Deal with THRX
May 14, 2013
Glaxo/THRX's Breo Ellipta Gets FDA Nod
May 13, 2013
Split News Overshadows Theravance's 1Q Loss
Apr 26, 2013
FDA Panel Backs GSK/THRX's Drug
Apr 18, 2013
GSK/THRX Drug to Face FDA Panel
Apr 16, 2013
Theravance Inks Deal for Vibativ
Mar 18, 2013
Glaxo/Theravance Seek US Approval
Feb 21, 2013
Theravance Narrows Y/Y Loss
Feb 13, 2013
Financials
| EPS TTM | -1.51 |
| Sales | 136 |
| Net Income | -141 |
| Price/Earnings | NA |
| Price/Book | 45.05 |
| Price/Cash Flow | NA |
| Price/Sales | 416.29 |
News
Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies - TheMotleyFool
May 15, 2013
Theravance Looks to Continue to Trade Above its Annual-High Share Price Today - Financial News Netwfork Online - 52-Week High-Lows
May 14, 2013
Who Benefits From This Market Moving Biotechnology Partnership? - TheMotleyFool
May 14, 2013
BREO(TM) ELLIPTA(TM) gains US approval for the treatment of COPD - M2
May 13, 2013
Benzinga`s Top Pre-Market Gainers - Benzinga
May 13, 2013
Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal - Pr Newswire
May 13, 2013
Elan Comments on Royalty Participation Agreement with Theravance - Benzinga
May 13, 2013
Market Wrap for Monday, May 13: Major Averages Closed Mixed as Retail Sales Data Surpasses Expectations - Benzinga
May 13, 2013
Broker Recommendations
| Current ABR | 1.63 |
| ABR (Last Week) | 1.92 |
| # of recs in ABR | 8 |
| Average Target Price | 46.33 |
| Industry Rank by ABR | 79 out of 265 |
| Rank in Industry | 33 out of 156 |
